Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|October 29, 2021

MilliporeSigma’s Millicell DCI Digital Cell Imager Offers Quick, Accurate, and Objective Cell Monitoring

MilliporeSigma’s newly launched Millicell DCI Digital Cell Imager quickly and objectively assesses common cell culture parameters and growth trends for more consistent cell cultures.

MilliporeSigma’s newly launched Millicell DCI Digital Cell Imager instrument helps improve cell culture productivity in the lab by assessing a broad range of parameters, including confluency, morphology, and cell growth trends, which provides a faster and more accurate analysis with reduced user bias, according to a company press release.

Millicell DCI, launched in October 2021, has an intuitive, built-in touchpad display that enables more efficient execution of repetitive daily laboratory techniques associated with cell passaging, screening, or manufacturing of cell-based products. The Millicell Cloud software operates on an off-device subscription and provides automated data analysis. The software also allows for access to the data from remote desktops or mobile devices. The remote feature saves on costs and supports data redundancy for backup as well as protection by automatically sorting and storing data and images. With this instant access to historical data, researchers can track cell culture trends and create consistent cell cultures.

The instrument also removes the requirement for manual manipulation of the cell culture flask, which can result in reduced contamination risk and improved flexibility users. Evaluation is also possible for a wide variety of cell cultures, including adherent cells and cell lines, spheroids, organoids. In addition, the instrument facilitates hemocytometer or in-vessel measurement.

Source: MilliporeSigma


Related to this article

The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.